Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Elevai Labs Inc (ELAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

10 Most Active Stocks On Stockwits In The Past Week With Message Volume Spurt Stocktwits - Mon Nov 18, 2:08AM CST

Cryptocurrencies, stocks that pulled back from their post-election highs, and some obscure securities were among those that saw huge message volumes in the past week.

Elevai Labs Inc. Reports Strong Financial Results and Advances in Aesthetic Innovation, Including Successful $8 Million Public Offering Quiver Quantitative, Inc. - Thu Nov 14, 6:56PM CST

Elevai Labs announces strong financial results, innovative clinical advancements, and expansion of its patent portfolio in aesthetic treatments.Quiver AI SummaryElevai Labs Inc. reported strong financial...

CORRECTION - Elevai Labs Inc. GlobeNewswire - Thu Nov 14, 1:35PM CST

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update GlobeNewswire - Thu Nov 14, 8:08AM CST

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange GlobeNewswire - Mon Nov 4, 4:45PM CST

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity GlobeNewswire - Tue Oct 22, 8:54AM CDT

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity GlobeNewswire - Mon Oct 21, 6:30AM CDT

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock GlobeNewswire - Fri Oct 4, 4:08PM CDT

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations GlobeNewswire - Thu Oct 3, 2:45PM CDT

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations GlobeNewswire - Thu Oct 3, 6:30AM CDT